Viewing Study NCT01132560


Ignite Creation Date: 2025-12-25 @ 2:16 AM
Ignite Modification Date: 2025-12-26 @ 5:04 PM
Study NCT ID: NCT01132560
Status: COMPLETED
Last Update Posted: 2017-05-17
First Post: 2010-05-26
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Biomarkers in Tissue Samples From Patients With Ductal Breast Carcinoma in Situ
Sponsor: ECOG-ACRIN Cancer Research Group
Organization:

Study Overview

Official Title: A Correlative Science Study for ECOG E5194
Status: COMPLETED
Status Verified Date: 2017-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is studying biomarkers in tissue samples from patients with ductal breast carcinoma in situ.
Detailed Description: OBJECTIVES:

* To validate the prognostic utility of a new ductal breast carcinoma in situ (DCIS) genomic score and the Oncotype DX Recurrence ScoreĀ® assay in tissue samples from patients with DCIS enrolled on clinical trial ECOG-E5194.

OUTLINE: RNA extracted from archived tissue samples are analyzed for gene expression profile by Oncotype DX Recurrence ScoreĀ® assay (a reverse transcriptase-PCR-based assay).

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
ECOG-E5194T1 None None View